Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Peter Bossuyt et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96